GlobeNewswire Inc.T3·23mo ago
KPRX Kiora Pharmaceuticals, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
KPRX
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 13
- List Date
- 2015-02-13
- CIK
- 0001372514
- Next Earnings
- 2026-11-06
- Headquarters
- Encinitas, CA
- Homepage
- https://www.kiorapharma.com
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -39.37% | 4.13% | -1.85% | 12.57% | 18.81% | -1.14% |
| Feb | -- | -18.35% | 24.30% | -21.06% | -15.14% | -10.68% | -8.19% |
| Mar | -- | -1.83% | -18.14% | 7.79% | -1.95% | -6.31% | -4.09% |
| Apr | -- | -15.23% | 32.93% | -16.23% | 9.90% | 20.51% | 6.38% |
| May | -- | -9.78% | -47.49% | -9.54% | -9.26% | 9.84% | -13.25% |
| Jun | -- | 13.07% | -61.39% | -5.15% | 1.05% | -6.24% | -11.73% |
| Jul | -- | -67.31% | -9.56% | 6.44% | -7.80% | -5.19% | -16.68% |
| Aug | -- | 30.29% | -16.31% | -18.32% | 9.45% | -3.09% | 0.40% |
| Sep | -- | -19.08% | 16.45% | 3.39% | 1.83% | 1.99% | 0.92% |
| Oct | -- | -7.59% | 0.00% | 1.40% | -18.37% | -14.34%* | -7.78% |
| Nov | -17.03% | -44.70% | -14.38% | -9.44% | -19.84% | -- | -21.08% |
| Dec | 8.63% | -6.79% | -4.15% | -4.07% | 2.07% | -- | -0.86% |
| Total | -9.87% | -93.10% | -79.35% | -52.47% | -35.22% | -0.95% | -45.16% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.46
SMA 50: $2.55
SMA 200: $2.42
Current: $2.21
EMA 12: $2.37
EMA 26: $2.46
MACD: -0.0838 | Signal: -0.0251
BEARISH
ADX (14): 22.78
WEAK TREND
+DI: 11.17
−DI: 28.55
Momentum Oscillators
RSI (14): 23.97
OVERSOLD
Stoch %K: 4.39
Stoch %D: 4.78
Williams %R: -100.00
Volume & Volatility
BB Upper: $2.68
BB Lower: $2.24
OVERSOLD
OBV: 49,525,888
Vol SMA 20: 14,322
Vol ROC: 95.64%
ATR: $0.08
True Range: $0.08
HV 20: 22.2%
HV 30: 28.8%
HV 60: 34.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: KPRX
Executive Summary: Overall assessment: NEUTRAL with confidence level (6/10) Key drivers: Technical indicators suggest a neutral trend, while recent news headlines are generally neutral. Primary risks include high volatility and the potential for a breakout above the upper Bollinger Band. Investment thesis: Kiora Pharmaceuticals' stock price is expected to oscillate within its current trading range, pending catalysts that could trigger significant moves.
Recent news sentiment impact: The recent news headlines have been largely neutral, with no significant events or announcements affecting the stock's price.
Technical Analysis:
- Trend Direction: Short-term (1-4 weeks): Sideways consolidation
- Support/Resistance Levels:
- SMA 20: $2.63 (support)
- Upper Bollinger Band: $2.83 (resistance)
- Momentum Signals:
- RSI interpretation: Neutral (53.42), not oversold or overbought
- MACD signal: Bullish (0.00 / Signal: -0.01 / Histogram: 0.02)
- Bollinger Bands position: Squeeze, with the price testing the upper band
- Volume Analysis: Volume is relatively low, indicating caution among investors.
News & Sentiment Analysis:
- Recent Headlines Summary: Neutral news headlines have dominated recent activity.
- Sentiment Assessment: Overall sentiment is neutral (4/5).
- Catalyst Identification: No significant catalysts are currently pending.
- Market Narrative: The neutral trend and low volume suggest a wait-and-see approach.
Risk & Volatility Assessment:
- Beta Interpretation: High risk relative to the market (beta 1.30).
- Volatility Regime: Current volatility is higher than historical levels.
- Options Market Signals: No options data available.
- Downside Protection: Support levels are present at SMA 20 ($2.63).
Market Context & Positioning:
- Sector Performance: Relative strength vs sector/market is neutral (0/5).
- Institutional Activity: No significant institutional activity has been observed recently.
- Correlation Analysis: Stock moves more than the market (R-squared 0.26).
- Relative Valuation: Position within trading range.
Key Levels & Action Items:
- Critical Price Levels: SMA 20 ($2.63), Upper Bollinger Band ($2.83)
- Breakout/Breakdown Levels: SMA 50, EMA 12
- Time-Sensitive Catalysts: No significant catalysts are currently pending.
- Risk Management: Stop-loss levels should be set at SMA 20 ($2.63) to manage risk.
Conclusion: Kiora Pharmaceuticals' stock price is expected to continue its neutral trend, pending catalysts that could trigger significant moves. The high volatility and potential for a breakout above the upper Bollinger Band are primary risks. A wait-and-see approach is recommended, with stop-loss levels set at SMA 20 ($2.63) to manage risk.
Generated
News
All KPRX news →
Zacks Investment ResearchT3·28mo ago
BenzingaT3·33mo ago
BenzingaT3·33mo ago
BenzingaT3·33mo ago
BenzingaT3·33mo ago
BenzingaT3·33mo ago
BenzingaT3·36mo ago
BenzingaT3·38mo ago
BenzingaT3·38mo ago
Showing 1–10 of 50
Page 1 of 5
KPRX Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.8931
Alpha: -11.17%
Correlation: 0.1997
R-Squared: 4.0%
Stock Volatility: 57.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own KPRX
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $305K | #5054 of 6285 | +134.2% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $195K | #3499 of 3716 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $78K | #3006 of 3138 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
KPRX Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
KPRX Insider Trading (Form 4)
Latest: 2026-09-17Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Keith J. Lane | Grant (A) | +55,000 opt | — | EDGAR | ||
| 2026-07-02 | Melissa Tosca | CFO | Tax (F) | −911 | $2.66 | -$2.4K | EDGAR |
| 2026-07-02 | Brian M. Strem | President and CEO | Tax (F) | −1,869 | $2.66 | -$5.0K | EDGAR |
| 2026-06-12 | Aron Shapiro | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-06-12 | Erin Parsons | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-06-12 | Carmine N. Stengone | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-06-12 | Praveen Tyle | Director | Grant (A) | +40,000 opt | — | EDGAR | |
| 2026-06-12 | David Hollander | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-06-12 | Lisa Walters-Hoffert | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-04-02 | Eric Joseph Daniels | Chief Development Officer | Tax (F) | −929 | $1.95 | -$1.8K | EDGAR |
| 2026-04-02 | Brian M. Strem | President and CEO | Tax (F) | −1,906 | $1.95 | -$3.7K | EDGAR |
| 2026-04-02 | Melissa Tosca | CFO | Tax (F) | −929 | $1.95 | -$1.8K | EDGAR |
| 2026-03-10 | Brian M. Strem | President and CEO | Award (A) | +16,733 | — | EDGAR | |
| 2026-03-10 | Melissa Tosca | CFO | Award (A) | +6,533 | — | EDGAR | |
| 2026-03-10 | Eric Joseph Daniels | Chief Development Officer | Award (A) | +6,533 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
KPRX Insider Holdings
8 insiders · @ $2.21
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Brian M. Strem | President and CEO | 58,823 | $130.0K | $40.2K | 12 | 2026-07-02 |
| 2 | Eric Joseph Daniels | Chief Development Officer | 31,741 | $70.1K | $7.6K | 12 | 2026-04-02 |
| 3 | Melissa Tosca | CFO | 26,064 | $57.6K | $6.9K | 10 | 2026-07-02 |
| 4 | Erin Parsons | Director | 5,260 | $11.6K | $25.7K | 7 | 2026-06-12 |
| 5 | Praveen Tyle | Director | 5,014 | $11.1K | $19.8K | 7 | 2026-06-12 |
| 6 | Aron Shapiro | Director | 3,000 | $6.6K | $10.8K | 7 | 2026-06-12 |
| 7 | Lisa Walters-Hoffert | Director | 1,250 | $2.8K | $4.8K | 4 | 2026-06-12 |
| 8 | Carmine N. Stengone | Director | 1,250 | $2.8K | $4.6K | 5 | 2026-06-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
KPRX Board & Officers
As of SEC filings through Sep 17, 2026Directors 7
- Praveen Tyle · since Feb 12, 2015
- Aron Shapiro · since Apr 1, 2021
- Brian M. Strem · since Jul 26, 2021
- David Hollander · since Dec 13, 2021
- Erin Parsons · since Jan 31, 2022
- Carmine N. Stengone · since Aug 1, 2023
- Lisa Walters-Hoffert · since Jul 1, 2024
Officers 2
- Brian M. Strem · President and CEO · since Jul 26, 2021
- Melissa Tosca · CFO · listed since Jul 2024
Changes in the last 10 years (36)
| Apr 1, 2026 | The company announced the departure of Eric Joseph Daniels as Chief Development Officer in an SEC filing |
| Jul 3, 2024 | Melissa Tosca listed as CFO (previously EVP Finance) in SEC filings |
| Jul 1, 2024 | Lisa Walters-Hoffert became a director |
| Sep 20, 2023 | The company announced the departure of Paul G Chaney from the board in an SEC filing |
| Aug 1, 2023 | Carmine N. Stengone became a director |
| Sep 13, 2022 | Melissa Tosca became EVP Finance |
| Jun 16, 2022 | The company announced the departure of Susan L. Drexler as Interim CFO in an SEC filing |
| Apr 21, 2022 | Susan L. Drexler became Interim CFO |
| Feb 9, 2022 | The company announced the departure of Sarah Romano as Chief Financial Officer in an SEC filing |
| Jan 31, 2022 | The company announced the departure of Stephen From from the board in an SEC filing |
| Jan 31, 2022 | The company announced the departure of Stephen From as Executive Chairman in an SEC filing |
| Jan 31, 2022 | Erin Parsons became a director |
| Dec 13, 2021 | David Hollander became a director |
| Nov 3, 2021 | Brenda Mann reported in an SEC filing no longer being VP of Research & Development |
| Oct 21, 2021 | Eric Joseph Daniels became Chief Development Officer |
| Jul 26, 2021 | Brian M. Strem became a director |
| Jul 26, 2021 | Brian M. Strem became President and CEO |
| Apr 1, 2021 | Kenneth L Gayron became a director |
| Apr 1, 2021 | Aron Shapiro became a director |
| Feb 3, 2021 | Stephen From listed as Executive Chairman (previously President and CEO) in SEC filings |
| Feb 1, 2021 | Franz Obermayr became Acting CEO |
| Jan 8, 2021 | Armistice Capital Master Fund Ltd. first listed as a director in an SEC filing |
| Aug 5, 2020 | Stephen From no longer listed as a 10% owner in SEC filings |
| Jul 6, 2020 | Stephen From first listed as a 10% owner in an SEC filing |
| Jan 10, 2020 | Illya Keith Maher became a director |
| Jul 10, 2018 | Peter Greenleaf became a director |
| May 30, 2018 | Armistice Capital Master Fund Ltd. no longer listed as a director in SEC filings |
| May 16, 2018 | Steven Boyd first listed as a director in an SEC filing |
| May 16, 2018 | Armistice Capital, LLC first listed as a director in an SEC filing |
| May 16, 2018 | Armistice Capital Master Fund Ltd. first listed as a director in an SEC filing |
| Apr 13, 2018 | Steven Boyd became a 10% owner |
| Apr 13, 2018 | Armistice Capital, LLC became a 10% owner |
| Apr 13, 2018 | Armistice Capital Master Fund Ltd. became a 10% owner |
| Jan 3, 2018 | Sarah Romano listed as Chief Financial Officer (previously Interim CFO) in SEC filings |
| Nov 1, 2017 | Michael Garanzini became Chief Commercial Officer |
| Feb 1, 2017 | Sarah Romano became Interim CFO |
Not reported recently (15)
- Kenneth L Gayron · Last reported as a director in an SEC filing dated Oct 3, 2023
- Michael P. Manzo · Last reported as VP of Engineering in an SEC filing dated Aug 4, 2021
- Steven Boyd · Last reported as a 10% owner in an SEC filing dated Aug 3, 2021
- Armistice Capital, LLC · Last reported as a 10% owner in an SEC filing dated Aug 3, 2021
- Armistice Capital Master Fund Ltd. · Last reported as a 10% owner in an SEC filing dated Aug 3, 2021
- Thomas Hancock · Last reported as a director in an SEC filing dated Feb 3, 2021
- Bernard Malfroy-Camine · Last reported as a director in an SEC filing dated Feb 3, 2021
- Morton Goldberg · Last reported as a director in an SEC filing dated Feb 3, 2021
- Franz Obermayr · Last reported as Acting CEO in an SEC filing dated Feb 3, 2021
- Illya Keith Maher · Last reported as a director in an SEC filing dated Jan 15, 2020
- Barbara Wirostko · Last reported as Chief Medical Officer in an SEC filing dated Aug 7, 2019
- Peter Greenleaf · Last reported as a director in an SEC filing dated Feb 5, 2019
- Michael Garanzini · Last reported as Chief Commercial Officer in an SEC filing dated Jul 12, 2018
- Thomas Balland · Last reported as a director in an SEC filing dated Jun 22, 2017
- Ventech Capital II · Last reported as a 10% owner in an SEC filing dated Mar 21, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
5 ETFs hold KPRX
5 shown · $79.29K total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $56,253 | — | 2026-09-30 |
| 2 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.00% | $8,827 | — | 2026-10-23 |
| 3 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $7,898 | — | 2026-10-23 |
| 4 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $3,542 | — | 2026-10-23 |
| 5 | DFSU Dimensional US Sustainability Core 1 ETF | Dimensional | 0.00% | $2,768 | $2.4B | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.